MG-H1, mAb 1H7G5
The MG-H1 antibody clone 1H7G5 recognizes methylglyoxal 5-hydro-5-methylimidazolones (MG-H1). Glycation, or nonenzymatic glycation, is the nonenzymatic reaction of glucose and other reducing sugars with free amino groups of proteins, lipids and nucleic acids. The amino groups of the side chains of arginine and lysine are the primary targets for this type of modification. Over time, the initial glycation products may undergo intramolecular rearrangements and oxidation reactions (glycoxidation) and ultimately transfrom in stable, so-called advanced glycation end products (AGEs). Several compounds, e.g. NƐ-carboxymethyl-lysine (CML), pentosidine, or methylglyoxal (MGO) derivates, serve as examples of well-characterized and widely studies AGEs. AGEs have the potential to interact with a specific receptor (RAGE), a member of the immunoglobulin superfamily, initiating signal pathways that amplify inflammation and oxidative stress, and thereby leading to cellular injury and death. High levels of circulating AGEs are associated with cardiovascular disease, diabetes, chronic kidney disease, and increased mortality. Methylglyoxal (MGO) is an endogenous product of glucose metabolism. Increased production and accumulation of MGO, as well as increased modification of proteins by glycoxidation, are hallmarks of aging and diabetes. MGO was shown to modify proteins and to contribute to the accumulation of damaged proteins that can be toxic to cells. Besides argpyrimidine and tetrahydropyrimidine, methylglyoxal hydroimidazolones (MG-Hs) comprise the most prevalent arginine-derived AGE. They are formed as a mixture of three isomers by protein glycation with MGO. MG-Hs are estimated to modify 1–2% of all arginine residues found in lens proteins of elderly human subjects. Levels of this AGE have also been found to be elevated in patients with cardiovascular disease, Alzheimer’s disease, and diabetes mellitus.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA